Advertisement

Topics

US FDA warns Chinese finished drug firm, cites GMP violations & misbranding

09:47 EST 8 Nov 2017 | in-PharmaTechnologis

Guangdong Zhanjiang Jimin Pharmaceutical Co. has received a warning letter from the US FDA citing cGMP violations as well as unapproved new drug and misbranding charges.

Original Article: US FDA warns Chinese finished drug firm, cites GMP violations & misbranding

NEXT ARTICLE

More From BioPortfolio on "US FDA warns Chinese finished drug firm, cites GMP violations & misbranding"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...